Abstract Overview: Sunitinib in Advanced/Metastatic Renal Cell Carcinoma
Brian Rini, MD of Cleveland Clinic gives an overview of his poster presentation which focuses on the use of sunitinib in advanced/metastatic renal cell carcinoma at the 2017 ASCO Annual Meeting in Chi...
Author: ASCO2017
Added: 06/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Can NKTR-214 Work For Other Cancers?
Adi Diab, MD of MD Anderson Cancer Center discusses a common question he's asked, regarding the use of NKTR-214 for not only renal cell carcinoma and melanoma, but for other cancers as well. This was ...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: Effect of IL-2 Cytokine Immune Agonist (NKTR-214)
Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at ...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: T-Cell Therapy for Merkel Cell Carcinoma
Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview and background context on her abstract which focuses on t-cell therapy merkel cell carcinoma. This was recorded at the 2017...
Author: ASCO2017
Added: 06/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Whats Next for T-Cell Therapy and Avelumab for Merkel Cell Carcinoma
Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance discusses what's next in the future for her clinical trial on t-cell therapy and avelumab for merkel cell carcinoma at the 2017 ASCO Annual M...
Author: ASCO2017
Added: 06/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Epitopes of Merkel Cell Polyomavirus
Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance explains what epitopes are in merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: ASCO2017
Added: 06/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Cellular Immunotherapy for Merkel Cell Carcinoma
Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview of her poster presentation which focuses on two trials of cellular immunotherapy for merkel cell carcinoma. This was record...
Author: ASCO2017
Added: 06/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Impact of Regorafenib for HCC
Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malign...
Author: GiDebates2017
Added: 05/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2017 Category: Cancer & Oncology Source Type: podcasts
Management of Anal Cancer
Cathy Eng, MD, FACP of MD Anderson Cancer Center discusses her second presentation, which focused on management of anal carcinoma. This was recorded at the 2017 Great Debates and Updates in GI Maligna...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Is There a Standard Second Line Therapy for HCC?
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains whether or not there is a standard second line treatment for patients with hepatocellular carcinoma (HCC) and who failed first line therapy. He ...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Are combination therapies the future of renal cell carcinoma treatment?
Grant Stewart, MBChB, FRCSEd (Urol), PhD, from the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses novel treatments for renal cell carcinoma (...
Author: VJOncology
Added: 05/09/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 9, 2017 Category: Cancer & Oncology Source Type: podcasts
Squamous cell carcinoma: Changing face of 1st and 2nd line therapy
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou discusses the changing face of first- and second-line therapy for squamous cell carcinoma...
Author: imedex
Added: 05/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 5, 2017 Category: Cancer & Oncology Source Type: podcasts
JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with m...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
Future Research Will Involve Combination Studies for Merkel Cell Carcinoma
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
Avelumab: New Agent Available for Merkel Cell Carcinoma
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the use of avelumab, a new agent that became available for patients with merkel cell carcinoma. This was recorded at the...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
